Equity Profile

AMGN

Amgen Inc.

Health CareBiotechnology$226.1B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Amgen Inc. is a biotechnology company that develops and manufactures innovative therapies for serious illnesses....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a critical indicator of profitability and will show how well Amgen is managing its costs and revenue.

$5.62

Revenue

Total revenue reflects the company's sales performance and market demand for its products, which is vital for growth.

$9.4B

Wall Street expectations, options signals, track record, and call prep available with Pro.

AMGN Q2-2026 Earnings Preview

Context

Company Snapshot

Amgen Inc. is a biotechnology company that develops and manufactures innovative therapies for serious illnesses. Operating in the health care sector, Amgen focuses on areas like oncology, cardiovascular disease, and inflammation, making it a key player in improving patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.24%

Avg Stock Reaction

-0.15%

Last Quarter Recap

In Q1-2026, Amgen reported an EPS of $5.15, exceeding expectations by 8.88%. The stock reacted positively, gaining 2.43% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Amgen to report strong earnings, with a consensus EPS of $5.62 and revenue of $9.4 billion. The company has consistently beaten EPS estimates in recent quarters.

Bull Case

If Amgen continues its trend of beating EPS estimates, it could signal strong underlying business performance and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if Amgen fails to meet expectations or provides weak guidance, it could raise concerns about its growth trajectory, leading to a negative market reaction.

Key Metrics to Watch

EPS

$5.62

Earnings per share (EPS) is a critical indicator of profitability and will show how well Amgen is managing its costs and revenue.

Revenue

$9.4B

Total revenue reflects the company's sales performance and market demand for its products, which is vital for growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $5.62?

A beat on EPS would reinforce Amgen's strong performance and could drive the stock price higher.

What is the outlook for revenue growth given the consensus of $9.4 billion?

Revenue growth is crucial for investor confidence, and any signs of weakness could lead to a sell-off.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Amgen's ability to leverage its recent product launches, which could drive revenue higher than expected.

Supporting Evidence

Amgen has consistently beaten EPS estimates, indicating strong operational management.

The options market pricing suggests a significant move, which could reflect investor anticipation of positive news.

Recent product developments may not be fully reflected in analyst models.

Key Risk

If revenue exceeds $9.6 billion, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on Amgen's ability to maintain its growth trajectory amid increasing competition in the biotechnology sector.

Bull Confirmed If

An EPS of $5.75 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $5.50 would support the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±3.48%

Historical Avg

±1.1%

Pricing rich

The options market is pricing in a potential move of about 3.48%, indicating that investors expect some volatility around the earnings report.

Options are pricing ±3.5% while AMGN has averaged ±1.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

24.6%

Calls (248K)P/C Ratio: 0.58Puts (419K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amgen beats expectations, history suggests the stock could rise by about 1.09% on the first day, confirming strong business momentum.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to minimal movement as investors digest the details.

Miss

A miss could lead to a decline of about 0.15% on the first day, as investors reassess their outlook on the company's growth prospects.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$15,001.00–$50,000.00

disclosed dollar ranges

Most Active Members

R-FLMaria Elvira SalazarRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their market reception.
2Any commentary on cost management and operational efficiency.
3Insights into competitive pressures in the biotechnology sector.
4Guidance on future revenue growth and market expansion plans.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Amgen Inc. is a biotechnology company that develops and manufactures innovative therapies for serious illnesses....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a critical indicator of profitability and will show how well Amgen is managing its costs and revenue.

$5.62

Revenue

Total revenue reflects the company's sales performance and market demand for its products, which is vital for growth.

$9.4B

Wall Street expectations, options signals, track record, and call prep available with Pro.

AMGN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.24%

Avg Stock Reaction

-0.15%

Last Quarter Recap

In Q1-2026, Amgen reported an EPS of $5.15, exceeding expectations by 8.88%. The stock reacted positively, gaining 2.43% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Amgen to report strong earnings, with a consensus EPS of $5.62 and revenue of $9.4 billion. The company has consistently beaten EPS estimates in recent quarters.

Bull Case

If Amgen continues its trend of beating EPS estimates, it could signal strong underlying business performance and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if Amgen fails to meet expectations or provides weak guidance, it could raise concerns about its growth trajectory, leading to a negative market reaction.

Key Metrics to Watch

EPS

$5.62

Earnings per share (EPS) is a critical indicator of profitability and will show how well Amgen is managing its costs and revenue.

Revenue

$9.4B

Total revenue reflects the company's sales performance and market demand for its products, which is vital for growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $5.62?

A beat on EPS would reinforce Amgen's strong performance and could drive the stock price higher.

What is the outlook for revenue growth given the consensus of $9.4 billion?

Revenue growth is crucial for investor confidence, and any signs of weakness could lead to a sell-off.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Amgen's ability to leverage its recent product launches, which could drive revenue higher than expected.

Supporting Evidence

Amgen has consistently beaten EPS estimates, indicating strong operational management.

The options market pricing suggests a significant move, which could reflect investor anticipation of positive news.

Recent product developments may not be fully reflected in analyst models.

Key Risk

If revenue exceeds $9.6 billion, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on Amgen's ability to maintain its growth trajectory amid increasing competition in the biotechnology sector.

Bull Confirmed If

An EPS of $5.75 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $5.50 would support the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±3.48%

Historical Avg

±1.1%

Pricing rich

The options market is pricing in a potential move of about 3.48%, indicating that investors expect some volatility around the earnings report.

Options are pricing ±3.5% while AMGN has averaged ±1.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

24.6%

Calls (248K)P/C Ratio: 0.58Puts (419K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amgen beats expectations, history suggests the stock could rise by about 1.09% on the first day, confirming strong business momentum.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to minimal movement as investors digest the details.

Miss

A miss could lead to a decline of about 0.15% on the first day, as investors reassess their outlook on the company's growth prospects.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$15,001.00–$50,000.00

disclosed dollar ranges

Most Active Members

R-FLMaria Elvira SalazarRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their market reception.
2Any commentary on cost management and operational efficiency.
3Insights into competitive pressures in the biotechnology sector.
4Guidance on future revenue growth and market expansion plans.